Biotech Growth Trust Past Earnings Performance
Past criteria checks 0/6
Biotech Growth Trust's earnings have been declining at an average annual rate of -31.9%, while the Capital Markets industry saw earnings growing at 14.9% annually. Revenues have been declining at an average rate of 31.8% per year.
Key information
-31.9%
Earnings growth rate
-33.0%
EPS growth rate
| Capital Markets Industry Growth | 16.3% |
| Revenue growth rate | -31.8% |
| Return on equity | -31.4% |
| Net Margin | 105.0% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biotech Growth Trust makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | -88 | -92 | 4 | 0 |
| 30 Jun 23 | -60 | -67 | 4 | 0 |
| 31 Mar 23 | -32 | -41 | 4 | 0 |
| 31 Dec 22 | -68 | -78 | 5 | 0 |
| 30 Sep 22 | -104 | -116 | 5 | 0 |
| 30 Jun 22 | -154 | -159 | 0 | 0 |
| 31 Mar 22 | -205 | -202 | -5 | 0 |
| 31 Dec 21 | -119 | -115 | -5 | 0 |
| 30 Sep 21 | -32 | -28 | -4 | 0 |
| 30 Jun 21 | 95 | 86 | 10 | 0 |
| 31 Mar 21 | 222 | 200 | 25 | 0 |
| 31 Dec 20 | 254 | 231 | 24 | 0 |
| 30 Sep 20 | 285 | 262 | 23 | 0 |
| 30 Jun 20 | 177 | 161 | 14 | 0 |
| 31 Mar 20 | 69 | 61 | 4 | 0 |
| 31 Dec 19 | -4 | -11 | 4 | 0 |
| 30 Sep 19 | -76 | -83 | 4 | 0 |
| 30 Jun 19 | -24 | -31 | 4 | 0 |
| 31 Mar 19 | 29 | 21 | 5 | 0 |
| 31 Dec 18 | 20 | 12 | 5 | 0 |
| 30 Sep 18 | 11 | 4 | 5 | 0 |
| 30 Jun 18 | -8 | -13 | 5 | 0 |
| 31 Mar 18 | -27 | -30 | 5 | 0 |
| 31 Dec 17 | 25 | 21 | 5 | 0 |
| 30 Sep 17 | 76 | 73 | 5 | 0 |
| 30 Jun 17 | 91 | 85 | 5 | 0 |
| 31 Mar 17 | 106 | 98 | 5 | 0 |
| 31 Dec 16 | 79 | 71 | 5 | 0 |
| 30 Sep 16 | 52 | 43 | 5 | 0 |
| 30 Jun 16 | -36 | -43 | 4 | 0 |
| 31 Mar 16 | -123 | -129 | 3 | 0 |
| 31 Dec 15 | -31 | -38 | 4 | 0 |
| 30 Sep 15 | 61 | 52 | 5 | 0 |
| 30 Jun 15 | 144 | 133 | 6 | 0 |
| 31 Mar 15 | 226 | 214 | 7 | 0 |
| 31 Dec 14 | 169 | 160 | 6 | 0 |
| 30 Sep 14 | 112 | 105 | 6 | 0 |
| 30 Jun 14 | 100 | 96 | 5 | 0 |
| 31 Mar 14 | 88 | 86 | 4 | 0 |
| 31 Dec 13 | 91 | 90 | 3 | 0 |
| 30 Sep 13 | 94 | 93 | 3 | 0 |
| 30 Jun 13 | 88 | 84 | 4 | 0 |
Quality Earnings: BIOG is currently unprofitable.
Growing Profit Margin: BIOG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOG is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare BIOG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOG is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (-12.2%).
Return on Equity
High ROE: BIOG has a negative Return on Equity (-31.36%), as it is currently unprofitable.